Recombinant vesicular stomatitis virus-vectored vaccine induces long-lasting immunity against Nipah virus disease

Novel henipavirus, Langya virus got worldwide concern after infecting over three dozen people in China. Henipaviruses as respiratory pathogen could trace another pandemic like deadly Nipah Virus (NiV). It produces highly fatal respiratory disease & encephalitis in humans in Bangladesh & India. No authorized remedy exists against NiV. Only ideal NiV vaccine would award to both fast-acting & long-lived protection. Researcher reported that a recombinant vesicular stomatitis virus-based (rVSV-based) vaccine expressing the NiV glycoprotein (rVSV-ΔG-NiVBG) that protected 100% NiV-associated lethality in nonhuman primates within a week. Objective of research is to assess the longevity of rVSV-ΔG-NiVBG. Researchers vaccinated African green monkeys (AGMs) in one year before challenging with a lethal dose of NiV. All vaccinated AGMs (whether receiving a single dose or prime-boosted) survived with no detectable clinical signs or NiV replication by producing humoral responses. Transcriptomic analyses showed that sign of adaptive immune correspond with vaccine-mediated protection. While vaccines for COVID-19 have given a durable protection, the research results suggest that rVSV-ΔG-NiVBG bring out a long-lasting immunity.

(AR)